Dr. Robert L Coleman
Claim this profileMore about Robert L Coleman
Clinical Trial Related
18 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Robert L Coleman has experience with
- Bevacizumab
- Carboplatin
- Gemcitabine Hydrochloride
- Paclitaxel
Breakdown of trials Robert L Coleman has run
Ovarian Carcinoma
Clear Cell Adenocarcinoma
Ovarian Cancer
Peritoneal Adenocarcinoma
Fallopian Tube Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert L Coleman specialize in?
Robert L Coleman focuses on Ovarian Carcinoma and Clear Cell Adenocarcinoma. In particular, much of their work with Ovarian Carcinoma has involved treating patients, or patients who are undergoing treatment.
Is Robert L Coleman currently recruiting for clinical trials?
No, Robert L Coleman is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Robert L Coleman has studied deeply?
Yes, Robert L Coleman has studied treatments such as Bevacizumab, Carboplatin, Gemcitabine Hydrochloride.
What is the best way to schedule an appointment with Robert L Coleman?
Apply for one of the trials that Robert L Coleman is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.